Chelating Agents for the Treatment of Systemic Iron Overload
The DOI matches its Crossref record.
Abstract
The first successful therapeutic iron chelator was desferrioxamine which was introduced in the late 1960's by Ciba (now Novartis). Desferrioxamine has been an extremely successful compound having received the MMW "Pharmaceutical of the year" award for 1991. It is a life saving and a life - prolonging drug which improves the quality of life. However it is not orally active and its administration is both uncomfortable and expensive. Over the past twenty years there has been a growing interest in the orally active iron chelators, deferiprone and exjade, both having been extensively studied. The ability of these compounds to mobilize iron from the heart and endocrine tissue has presented the clinician with some advantages over desferrioxamine. Other orally active iron chelators are currently under development and one, FBS0701 is in clinical trial. The critical features necessary for the design of therapeutically useful iron chelators is presented in this review, together with recent studies devoted to the design of such chelators. This newly emerging range of iron chelators will enable clinicians to apply iron chelation methodology to other disease states and to begin to design personalised chelation regimes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Kell, D. B., & Pretorius, E. (2014) · Metallomics · doi:10.1039/c3mt00347g · Cited by 667
Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease
Devos, D., Moreau, C., Devedjian, J. C., Kluza, J., Petrault, M., Laloux, C., Jonneaux, A., Ryckewaert, G., Garçon, G., Rouaix, N., et al. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5593 · Cited by 619
Labile iron in cells and body fluids: Physiology, pathology, and pharmacology
Cabantchik, Z. I. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00045 · Cited by 306
“…transfer to extracellular transferrin (Tf) and recapture by receptor-mediated endocytosis-RME. www.frontiersin.org March 2014 | Volume 5 | Article 45 | 3 the most direct mode of pharmacological intervention (Hershko et al., 2005; Pietrangelo, 2007; Porter, 2009; Ma et al., 2012; Camaschella, 2013).”
BackgroundMethodInfluentialLeal, S. M., Roy, S., Vareechon, C., Carrion, S. D., Clark, H., Lopez-Berges, M. S., diPietro, A., Schrettl, M., Beckmann, N., Redl, B., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003436 · Cited by 111
“Deferiprone has been used effectively and safely to lower iron levels in patients with hemochromatosis [48], and although widely utilized in Europe, it is not currently licensed in the USA.”
Background
Metadata
- Authors
- Ma, Y., Zhou, T., Kong, X., & C. Hider, R.
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2012-05-01
- Volume
- 19
- Issue
- 17
- Pages
- 2816-2827
- ISSN
- 0929-8673 (ISSN-L)
- OpenAlex
- W2120764993
- Cited by
- 87
- References
- 0
- FWCI
- 7.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chelating Agents for the Treatment of Systemic Iron Overload. https://app.cochat.ai/papers/10.2174/092986712800609724
- The paper
- Ma, Y., Zhou, T., Kong, X., & C. Hider, R. (2012). Chelating Agents for the Treatment of Systemic Iron Overload. Current Medicinal Chemistry. https://doi.org/10.2174/092986712800609724
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.